# Staar Surgical Co: Form 10-Q for the period ended Jul 3, 2020

- Company: [Staar Surgical Co](/companies/staa.md) (CIK 718937)
- Form: 10-Q
- Filed: 2020-08-05
- Accepted by EDGAR: Aug 5, 2020, 16:12 ET
- Period: 2020-07-03
- Accession: 0001564590-20-036814
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/718937/000156459020036814/staa-10q_20200703.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/718937/000156459020036814/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2020-07-03.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2020-04-04 to 2020-07-03 | $4.5m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 6 months, 2020-01-04 to 2020-07-03 | $10.3m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months, 2020-04-04 to 2020-07-03 | $10.8m | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 6 months, 2020-01-04 to 2020-07-03 | $21.2m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months, 2020-04-04 to 2020-07-03 | $24.4m | us-gaap:GrossProfit |
| Gross profit | 6 months, 2020-01-04 to 2020-07-03 | $49.2m | us-gaap:GrossProfit |
| Research and development | 3 months, 2020-04-04 to 2020-07-03 | $7.3m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months, 2020-01-04 to 2020-07-03 | $14.2m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months, 2020-04-04 to 2020-07-03 | $25.5m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 6 months, 2020-01-04 to 2020-07-03 | $51.4m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months, 2020-04-04 to 2020-07-03 | −$1.1m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months, 2020-01-04 to 2020-07-03 | −$2.2m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months, 2020-04-04 to 2020-07-03 | $556.0k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months, 2020-01-04 to 2020-07-03 | −$602.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2020-04-04 to 2020-07-03 | −$1.2m | us-gaap:NetIncomeLoss |
| Net income | 6 months, 2020-01-04 to 2020-07-03 | −$1.3m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2020-04-04 to 2020-07-03 | −$0.03 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months, 2020-01-04 to 2020-07-03 | −$0.03 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2020-04-04 to 2020-07-03 | −$0.03 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months, 2020-01-04 to 2020-07-03 | −$0.03 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2020-04-04 to 2020-07-03 | 45,354,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months, 2020-01-04 to 2020-07-03 | 45,152,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months, 2020-01-04 to 2020-07-03 | −$8.2m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months, 2020-01-04 to 2020-07-03 | $4.2m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2020-07-03 | $116.3m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2020-07-03 | $182.5m | us-gaap:AssetsCurrent |
| Total assets | at 2020-07-03 | $218.0m | us-gaap:Assets |
| Current liabilities | at 2020-07-03 | $31.6m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2020-07-03 | $43.4m | us-gaap:Liabilities |
| Shareholders' equity | at 2020-07-03 | $174.7m | us-gaap:StockholdersEquity |

## Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. https://www.sec.gov/Archives/edgar/data/718937/000156459020036814/staa-10q_20200703.htm

Filed Aug 5, 2020.
Source: SEC EDGAR, the filing index for accession 0001564590-20-036814. Last ingested by Listed: Nov 4, 2026, 17:00 ET. No prices; not investment advice.
